EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
S&P 500   3,954.36 (-0.24%)
DOW   33,819.50 (-0.09%)
QQQ   280.16 (-0.90%)
AAPL   140.50 (-2.58%)
MSFT   239.97 (-0.74%)
META   109.95 (+1.08%)
GOOGL   94.97 (-1.12%)
AMZN   92.27 (-1.79%)
TSLA   179.52 (-1.86%)
NVDA   156.53 (-1.10%)
NIO   10.54 (+4.15%)
BABA   79.94 (+5.35%)
AMD   73.67 (+0.66%)
T   18.92 (+0.53%)
MU   55.00 (-1.35%)
CGC   3.44 (+1.18%)
F   13.73 (+0.00%)
GE   85.30 (-0.20%)
DIS   94.10 (-1.66%)
AMC   7.42 (+1.23%)
PYPL   77.93 (-2.50%)
PFE   49.42 (-0.30%)
NFLX   279.37 (-0.64%)
S&P 500   3,954.36 (-0.24%)
DOW   33,819.50 (-0.09%)
QQQ   280.16 (-0.90%)
AAPL   140.50 (-2.58%)
MSFT   239.97 (-0.74%)
META   109.95 (+1.08%)
GOOGL   94.97 (-1.12%)
AMZN   92.27 (-1.79%)
TSLA   179.52 (-1.86%)
NVDA   156.53 (-1.10%)
NIO   10.54 (+4.15%)
BABA   79.94 (+5.35%)
AMD   73.67 (+0.66%)
T   18.92 (+0.53%)
MU   55.00 (-1.35%)
CGC   3.44 (+1.18%)
F   13.73 (+0.00%)
GE   85.30 (-0.20%)
DIS   94.10 (-1.66%)
AMC   7.42 (+1.23%)
PYPL   77.93 (-2.50%)
PFE   49.42 (-0.30%)
NFLX   279.37 (-0.64%)
S&P 500   3,954.36 (-0.24%)
DOW   33,819.50 (-0.09%)
QQQ   280.16 (-0.90%)
AAPL   140.50 (-2.58%)
MSFT   239.97 (-0.74%)
META   109.95 (+1.08%)
GOOGL   94.97 (-1.12%)
AMZN   92.27 (-1.79%)
TSLA   179.52 (-1.86%)
NVDA   156.53 (-1.10%)
NIO   10.54 (+4.15%)
BABA   79.94 (+5.35%)
AMD   73.67 (+0.66%)
T   18.92 (+0.53%)
MU   55.00 (-1.35%)
CGC   3.44 (+1.18%)
F   13.73 (+0.00%)
GE   85.30 (-0.20%)
DIS   94.10 (-1.66%)
AMC   7.42 (+1.23%)
PYPL   77.93 (-2.50%)
PFE   49.42 (-0.30%)
NFLX   279.37 (-0.64%)
S&P 500   3,954.36 (-0.24%)
DOW   33,819.50 (-0.09%)
QQQ   280.16 (-0.90%)
AAPL   140.50 (-2.58%)
MSFT   239.97 (-0.74%)
META   109.95 (+1.08%)
GOOGL   94.97 (-1.12%)
AMZN   92.27 (-1.79%)
TSLA   179.52 (-1.86%)
NVDA   156.53 (-1.10%)
NIO   10.54 (+4.15%)
BABA   79.94 (+5.35%)
AMD   73.67 (+0.66%)
T   18.92 (+0.53%)
MU   55.00 (-1.35%)
CGC   3.44 (+1.18%)
F   13.73 (+0.00%)
GE   85.30 (-0.20%)
DIS   94.10 (-1.66%)
AMC   7.42 (+1.23%)
PYPL   77.93 (-2.50%)
PFE   49.42 (-0.30%)
NFLX   279.37 (-0.64%)
NASDAQ:BIIB

Biogen - BIIB Stock Forecast, Price & News

$290.59
-1.31 (-0.45%)
(As of 11/29/2022 02:59 PM ET)
Add
Compare
Today's Range
$288.49
$293.94
50-Day Range
$195.75
$306.72
52-Week Range
$187.16
$307.53
Volume
29,218 shs
Average Volume
1.08 million shs
Market Capitalization
$41.84 billion
P/E Ratio
14.80
Dividend Yield
N/A
Price Target
$299.75

Biogen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
2.9% Upside
$299.75 Price Target
Short Interest
Healthy
1.69% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.79
Upright™ Environmental Score
News Sentiment
-0.03mentions of Biogen in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$1.55 M Sold Last Quarter
Proj. Earnings Growth
-6.87%
From $17.03 to $15.86 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

504th out of 1,038 stocks

Biological Products, Except Diagnostic Industry

81st out of 172 stocks

BIIB stock logo

About Biogen (NASDAQ:BIIB) Stock

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Stock News Headlines

Moderna, Biogen rise; Oatly, Dentsply fall
Stocks that traded heavily or had substantial price changes Monday: Moderna, Biogen rise; Oatly, Dentsply fall
Biogen tabs veteran pharma leader Viehbacher as next CEO
Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the Alzheimer’s treatment Aduhelm
Midday movers: Wynn Resorts, Biogen, Apple and more
Biogen Stock Drops After Report of Patient Death
2 Biotech Stocks to Add to Your Portfolio in Q4
3 Stocks to Buy This Month if You Haven’t Already
Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer
The 4 Best Stocks to Buy This November
2 Stocks You Could Keep in Your Portfolio Forever
Is Biogen (BIIB) a Great Value Stock Right Now?
See More Headlines
Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Company Calendar

Last Earnings
10/25/2022
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/02/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
Employees
9,610
Year Founded
1978

Price Target and Rating

Average Stock Price Forecast
$299.75
High Stock Price Forecast
$370.00
Low Stock Price Forecast
$217.00
Forecasted Upside/Downside
+3.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
28 Analysts

Profitability

Net Income
$1.56 billion
Pretax Margin
32.74%

Debt

Sales & Book Value

Annual Sales
$10.98 billion
Cash Flow
$25.88 per share
Book Value
$74.61 per share

Miscellaneous

Free Float
143,065,000
Market Cap
$41.84 billion
Optionable
Optionable
Beta
0.19

Social Links


Key Executives

  • Michel VounatsosMichel Vounatsos
    Chief Executive Officer & Director
  • Alphonse Galdes
    EVP-Pharmaceutical Operations & Technology
  • Michael R. McDonnell
    Chief Financial Officer & Executive Vice President
  • Mahalakshmi Radhakrishnan
    Chief Medical Officer & Group Senior VP
  • Priya Singhal
    Head-Research & Development













BIIB Stock - Frequently Asked Questions

Should I buy or sell Biogen stock right now?

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 8 hold ratings and 20 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings
or view top-rated stocks.

What is Biogen's stock price forecast for 2023?

28 Wall Street analysts have issued 12 month target prices for Biogen's stock. Their BIIB share price forecasts range from $217.00 to $370.00. On average, they expect the company's stock price to reach $299.75 in the next year. This suggests a possible upside of 2.7% from the stock's current price.
View analysts price targets for BIIB
or view top-rated stocks among Wall Street analysts.

How have BIIB shares performed in 2022?

Biogen's stock was trading at $239.92 at the beginning of the year. Since then, BIIB stock has increased by 21.7% and is now trading at $291.90.
View the best growth stocks for 2022 here
.

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our BIIB earnings forecast
.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) posted its quarterly earnings data on Tuesday, October, 25th. The biotechnology company reported $4.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.16 by $0.61. The biotechnology company had revenue of $2.51 billion for the quarter, compared to analysts' expectations of $2.47 billion. Biogen had a net margin of 27.64% and a trailing twelve-month return on equity of 21.31%. The firm's revenue for the quarter was down 9.7% on a year-over-year basis. During the same period in the prior year, the firm earned $4.77 earnings per share.
Read the conference call transcript
.

What guidance has Biogen issued on next quarter's earnings?

Biogen updated its FY 2022 earnings guidance on Tuesday, November, 1st. The company provided earnings per share guidance of $16.50-$17.15 for the period, compared to the consensus estimate of $16.49. The company issued revenue guidance of $10.00 billion-$10.15 billion, compared to the consensus revenue estimate of $10.00 billion.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (10.93%), BlackRock Inc. (9.62%), Vanguard Group Inc. (8.27%), State Street Corp (4.79%), Point72 Asset Management L.P. (1.17%) and Price T Rowe Associates Inc. MD (1.07%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Michel Vounatsos, Stephen A Sherwin and Susan H Alexander.
View institutional ownership trends
.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $291.90.

How much money does Biogen make?

Biogen (NASDAQ:BIIB) has a market capitalization of $42.03 billion and generates $10.98 billion in revenue each year. The biotechnology company earns $1.56 billion in net income (profit) each year or $19.64 on an earnings per share basis.

How many employees does Biogen have?

The company employs 9,610 workers across the globe.

Does Biogen have any subsidiaries?
The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.

This page (NASDAQ:BIIB) was last updated on 11/29/2022 by MarketBeat.com Staff